Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).
NEW YORK – Oncologists used Reveal Genomics' predictive assay, HER2DX, to alter neoadjuvant and adjuvant ... 57 percent had another anti-HER2 agent added to Genentech's Herceptin (trastuzumab), such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback